NEW YORK (GenomeWeb News) – Knome has raised almost $5.8 million toward a targeted goal of $6.3 million, the bioinformatics firm said recently in a regulatory document.
The company did not respond to a request for comment. It did not say in its Form D filed with the US Securities and Exchange Commission who the investors are or how the funds would be used.
The securities offered were in the form of debt.
Based in Cambridge, Mass., Knome provides human genome interpretation software and services. In June, it said that it would offer Omixon's targeted human leukocyte antigen typing capabilities as part of its whole genome and exome interpretation pipelines. That followed a deal with Real Time Genomics to integrate the Real Time Genomics Variant platform into every shipment of the knoSys 100 interpretation system.
In August 2011, Knome said in an SEC document that it raised $5 million in a financing round that targeted $20 million.